Clearmind Medicine Inc.

CMND Healthcare Biotechnology

In the quarter to July 2026, EPS grew 99.4%, free cash flow fell 77.9% and total debt rose 10,410.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.26 0.16 −2.49%
Market cap
$3.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jul '26 Apr '26 Jan '26 Oct '25 Older periods
Current Ratio
4.31 4.79 3.79 1.22

+8 more quarters

Net Debt/EBITDA
6.53 8.64 2.83 2.63
Debt/Equity
0.13 0.00 0.00 1.48
Free Cash Flow per Share
(1.22) (5.85) (17.94) (101.24)
Book value per Share
8.19 38.05 70.90 93.91
Free Cash Flow
(1.93) (1.77) (2.08) (1.29)
Other line items

Show all line items

Columns are period end dates